Please ensure Javascript is enabled for purposes of website accessibility

Why Snap, Seattle Genetics, and Pretium Resources Jumped Today

By Dan Caplinger - Oct 11, 2017 at 5:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These stocks led the market higher. Find out why.

Wednesday was a generally good day for investors on Wall Street, featuring a gentle rise of about 0.15% to 0.25% for major benchmarks like the Dow and the S&P 500. The White House continued to make its case for the tax reform proposal it has put before lawmakers, and the release of the latest minutes from the Federal Reserve's meeting last month also hinted that the central bank wants to be careful not to tighten monetary policy too quickly. In addition to the generally positive mood among investors, some individual stocks had encouraging news that lifted their shares higher. Snap (SNAP 4.71%), Seattle Genetics (SGEN -0.14%), and Pretium Resources (PVG) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well.

Is Snap finally finding its way?

Shares of Snap climbed 11.5% as analysts looked favorably at the social media company's latest efforts to try to make itself more relevant in a crowded competitive space. Analysts at Credit Suisse raised their price target on Snap stock from $17 to $20 per share, arguing that the company's attempts to offer an easier way for advertisers to adapt their promotional materials to a vertically oriented screen format could help give Snap an edge over other mobile-oriented advertisers. Although a new strategy could cost Snap in the short run, it promises positive long-term network effects if it succeeds in drawing a wider customer base. Even after today's gains, Snap is still below its IPO price, but shareholders are getting more optimistic about its future.

Special customized Snap glasses.

Snap Spectacles. Image source: Snap.

Seattle Genetics keeps moving forward

Seattle Genetics stock gained 6.5% after making a couple of intriguing announcements. The company said yesterday that it had begun its phase 2 clinical trial of enfortumab vedotin, a candidate drug developed in conjunction with partner Astellas Pharma for treatment of urothelial cancer. In addition, Seattle Genetics will collaborate with a couple of other partners in evaluating its SGN-LIV1A antibody-drug conjugate in treating a form of breast cancer. The biotech company is still losing considerable amounts of money, but it's hopeful that a healthy pipeline of potential marketable treatments could turn the tide toward profitability if successful.

Pretium shines

Finally, shares of Pretium Resources soared 25%. The British Columbian mining company released its third-quarter production figures, which included more than 82,000 ounces of gold and a gold recovery rate of almost 96.5%. The company's Brucejack mine has proven to be intriguing, with high ore grades and improving processing speeds. Having worked through some low-grade stockpiles, Pretium's production accelerated toward the end of the quarter, and investors were pleased to see the company's mining operations paying off. As overall bullishness on gold increases, more investors will be looking at miners like Pretium to produce big gains.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool recommends Seattle Genetics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seagen Inc. Stock Quote
Seagen Inc.
SGEN
$175.36 (-0.14%) $0.24
Pretium Resources Inc. Stock Quote
Pretium Resources Inc.
PVG
Snap Inc. Stock Quote
Snap Inc.
SNAP
$10.64 (4.71%) $0.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.